Skip to main content

Table 1 Clinicopathological features of 356 patients who were treated with preoperative chemotherapy

From: Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age

Parameters All patients (n = 356) (%) Younger (n = 75) (%) Elderly (n = 116) (%)
Age (years) 55 (24–78) 41 (24–45) 67 (61–78)
Tumor size (mm) 28.7 (9.2–119.8) 29.5 (9.9–82.6) 27.3 (9.2–89.8)
Skin infiltration
 Negative/positive 298 (83.7%)/58 (16.3%) 68 (90.7%)/7 (9.3%) 90 (77.6%)/26 (22.4%)
Lymph node metastasis
 N0/N1/N2/N3 121 (33.9%)/133 (37.4%)/68 (19.1%)/34(9.6%) 28 (37.3%)/28 (37.3%)/14 (18.7%)/5 (6.7%) 44 (37.9%)/36 (31.0%)/22 (19.0%)/14(12.1%)
Estrogen receptor
 Negative/positive 187 (52.5%)/169 (47.5%) 37 (49.3%)/38 (50.7%) 67 (57.8%)/49 (42.2%)
Progesterone receptor
 Negative/positive 242 (68.0%)/114 (32.0%) 42 (56.0%)/33 (44.0%) 89 (76.7%)/27 (23.3%)
HER2
 Negative/positive 231 (64.9%)/125 (35.1%) 47 (62.7%)/28 (37.3%) 69 (59.5%)/47 (40.5%)
Ki67
 ≤ 14 %/> 14 % 117 (32.9%)/239 (67.1%) 22 (29.3%)/53 (70.7%) 40 (34.5%)/76 (65.5%)
Intrinsic subtype
 HR+HER2-BC/HR+HER2+BC/HER2BC/TNBC 126 (35.4%)/47 (13.2%)/78 (21.9%)/105 (29.5%) 24 (32.0%)/16 (21.3%)/12 (16.0%)/23 (30.7%) 39 (33.6%)/11 (9.5%)/36 (31.0%)/30 (25.9%)
Objective response rate
 Non-responders/responders 40 (11.2%)/316 (88.8%) 5 (6.7%)/70 (93.3%) 17 (14.7%)/99 (85.3%)
Pathological response
 Non-pCR/pCR 238 (66.9%)/118 (33.1%) 46 (61.3%)/29 (38.7%) 78 (67.2%)/38 (32.8%)
TILs
 Low/high 195 (54.5%)/161 (45.2%) 31 (41.3%)/44 (58.7%) 65 (56.0%)/51 (44.0%)
  1. HER human epidermal growth factor receptor, CR complete response, TILs tumor-infiltrating lymphocytes